AU2004279441B2 - Methods and compositions for diagnosis and treatment of B cell chronic lymphocytic leukemia - Google Patents

Methods and compositions for diagnosis and treatment of B cell chronic lymphocytic leukemia Download PDF

Info

Publication number
AU2004279441B2
AU2004279441B2 AU2004279441A AU2004279441A AU2004279441B2 AU 2004279441 B2 AU2004279441 B2 AU 2004279441B2 AU 2004279441 A AU2004279441 A AU 2004279441A AU 2004279441 A AU2004279441 A AU 2004279441A AU 2004279441 B2 AU2004279441 B2 AU 2004279441B2
Authority
AU
Australia
Prior art keywords
antibody
cll
chain antibody
gene
antibody gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004279441A
Other languages
English (en)
Other versions
AU2004279441A1 (en
Inventor
Emilia Albesiano
Nicholas Chiorazzi
Bradley T. Messmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The Feinstein Institutes for Medical Research
Original Assignee
The Feinstein Institutes for Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Feinstein Institutes for Medical Research filed Critical The Feinstein Institutes for Medical Research
Publication of AU2004279441A1 publication Critical patent/AU2004279441A1/en
Assigned to THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH reassignment THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH Amend patent request/document other than specification (104) Assignors: NORTH SHORE-LONG ISLAND JEWISH RESEARCH INSTITUTE
Application granted granted Critical
Publication of AU2004279441B2 publication Critical patent/AU2004279441B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2004279441A 2003-10-08 2004-10-08 Methods and compositions for diagnosis and treatment of B cell chronic lymphocytic leukemia Ceased AU2004279441B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50947303P 2003-10-08 2003-10-08
US60/509,473 2003-10-08
PCT/US2004/033176 WO2005034733A2 (en) 2003-10-08 2004-10-08 Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia

Publications (2)

Publication Number Publication Date
AU2004279441A1 AU2004279441A1 (en) 2005-04-21
AU2004279441B2 true AU2004279441B2 (en) 2010-07-01

Family

ID=34434984

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004279441A Ceased AU2004279441B2 (en) 2003-10-08 2004-10-08 Methods and compositions for diagnosis and treatment of B cell chronic lymphocytic leukemia

Country Status (6)

Country Link
US (2) US8119340B2 (cg-RX-API-DMAC7.html)
EP (1) EP1678195A4 (cg-RX-API-DMAC7.html)
JP (1) JP2007510622A (cg-RX-API-DMAC7.html)
AU (1) AU2004279441B2 (cg-RX-API-DMAC7.html)
CA (1) CA2541360A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005034733A2 (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
CA2541360A1 (en) 2003-10-08 2005-04-21 Bradley T. Messmer Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia
US20070105165A1 (en) * 2005-11-04 2007-05-10 Charles Goolsby Composite profiles of cell antigens and target signal transduction proteins for analysis and clinical management of hematologic cancers
US7767206B2 (en) * 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
IL299365A (en) 2010-05-27 2023-02-01 Genmab As Monoclonal antibodies against 2HER
NZ604007A (en) 2010-05-27 2015-03-27 Genmab As Monoclonal antibodies against her2 epitope
EP3957653A1 (en) * 2010-06-02 2022-02-23 Dana Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
WO2012143524A2 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
US9175082B2 (en) 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
DE102012212025A1 (de) * 2012-07-10 2014-01-16 Osram Gmbh Leuchtmodul
EP2741084B1 (en) 2012-12-07 2020-01-22 AVA Lifescience GmbH Method of prognosing the clinical course of chronic lymphocytic leukemia (CLL)
JP2016507520A (ja) 2013-01-23 2016-03-10 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 安定化されたb型肝炎コアポリペプチド
RS64268B1 (sr) 2013-09-20 2023-07-31 Bristol Myers Squibb Co Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
EA201691765A1 (ru) 2014-03-14 2016-12-30 Новартис Аг Молекулы антител против lag-3 и их применения
US9976146B2 (en) * 2014-05-30 2018-05-22 Academia Sinica Aptamer targeting MAGE-A3 peptide and uses thereof
US20180340025A1 (en) 2015-07-29 2018-11-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3
WO2017023859A1 (en) * 2015-07-31 2017-02-09 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins targeting cd56 and uses thereof
US20170073397A1 (en) * 2015-08-24 2017-03-16 Medimmune, Llc MrkA Polypeptides, Antibodies, and Uses Thereof
AU2016319126A1 (en) 2015-09-10 2018-04-19 Affigen, Inc. Sequencing-directed selection of tumor theranostics
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
US10836810B2 (en) 2017-02-17 2020-11-17 Mapp Biopharmaceutical, Inc. Monoclonal antibodies and cocktails for treatment of ebola infections
WO2018222718A1 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Treatment of lag-3 positive tumors
JP7301002B2 (ja) 2017-05-30 2023-06-30 ブリストル-マイヤーズ スクイブ カンパニー 抗lag-3抗体または抗lag-3抗体および抗pd-1もしくは抗pd-l1抗体を含む組成物
CN109752548B (zh) * 2019-02-01 2022-05-06 广州金域医学检验中心有限公司 评估慢性淋巴细胞白血病预后的组合试剂及系统
US12378321B2 (en) 2019-03-08 2025-08-05 Memorial Sloan Kettering Cancer Center ADAM17 binding molecules and uses thereof
EP4013794A4 (en) 2019-08-12 2023-11-22 City of Hope ANTI-IL1RAP ANTIBODIES
CA3196496A1 (en) 2020-10-23 2022-04-28 Laurence David TOMS Lag-3 antagonist therapy for lung cancer
EP4341289A1 (en) * 2021-05-18 2024-03-27 Christian-Albrechts-Universität zu Kiel Co-stimulatory multispecific antibodies
CN113461818B (zh) * 2021-06-30 2022-01-21 徐州医科大学 靶向CD276的全人源抗体scFv、嵌合抗原受体、工程化免疫细胞及其制备方法
AU2023231622A1 (en) * 2022-03-07 2024-09-26 Agenus Inc. Anti-ilt2 antibodies and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP2270049A3 (en) * 2002-04-12 2011-03-09 Medimmune, Inc. Recombinant anti-interleukin-9-antibody
CA2541360A1 (en) 2003-10-08 2005-04-21 Bradley T. Messmer Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CARTER, P., Nat. Rev. Cancer. 2001, vol. 1, no. 2, pages 118-129 (Y) *
CHIORAZZI, N. et al., Annual Review of Immunology, April 2003, vol. 21, pages 841-894 (Y) *
CHIORAZZI, N. et al., In Chronic lymphoid leukemia, 2nd Ed. B.D. Cheson, editor Marcel Dekker, New York. 2001, pages 81-109 (Y) *
DAMLE et al., Blood. 1999, Vo1.94, pages 1840-1847 (Y) *
FAIS et al., J. Clin. Invest. 1998, Vol. 102, pages 1515-1525 (Y) *
VALETTO, A . et al., Blood, 1998, vol. 92, no. 10 SUPPL. 1, PART 1-2, page 431A (Y) *

Also Published As

Publication number Publication date
WO2005034733A2 (en) 2005-04-21
US20120141462A1 (en) 2012-06-07
AU2004279441A1 (en) 2005-04-21
JP2007510622A (ja) 2007-04-26
EP1678195A2 (en) 2006-07-12
US20090117095A1 (en) 2009-05-07
EP1678195A4 (en) 2008-04-23
WO2005034733A3 (en) 2005-09-09
CA2541360A1 (en) 2005-04-21
US9745364B2 (en) 2017-08-29
US8119340B2 (en) 2012-02-21

Similar Documents

Publication Publication Date Title
US9745364B2 (en) Methods and compositions for diagnosis and treatment of B cell chronic lymphocytic leukemia
Messmer et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia
Marasca et al. Immunoglobulin gene mutations and frequent use of VH1-69 and VH4-34 segments in hepatitis C virus-positive and hepatitis C virus-negative nodal marginal zone B-cell lymphoma
Hardy et al. A single VH gene is utilized predominantly in anti-BrMRBC hybridomas derived from purified Ly-1 B cells. Definition of the VH11 family.
Craig et al. Gastric MALT lymphoma B cells express polyreactive, somatically mutated immunoglobulins
CN101668853B (zh) 癌抗原特异性t细胞受体基因、由该基因编码的肽及其使用
Bos et al. Monoclonal immunoglobulin A derived from peritoneal B cells is encoded by both germ line and somatically mutated VH genes and is reactive with commensal bacteria
EP3722314A1 (en) Anti-vista antibodies and fragments
CA2445989A1 (en) Colon cancer antigen panel
JPH07503062A (ja) 慢性関節リューマチの診断と治療用のVα12.1T細胞リセプターに特異的な試薬
Ghosh et al. In situ diversification of the antibody repertoire in chronic Lyme arthritis synovium
Feeney et al. Human cord blood kappa repertoire
US8722350B2 (en) Methods and compositions for categorizing patients
JP2008527998A (ja) Nsclcの診断のためのgitr抗体
US7118912B2 (en) Methods and compositions for categorizing patients
Roers et al. Single-cell PCR analysis of T helper cells in human lymph node germinal centers
Diaw et al. Double producers of kappa and lambda define a subset of B cells in mouse plasmacytomas
Dyer et al. Unusual deletions within the immunoglobulin heavy-chain locus in acute leukemias
Smilevska et al. Immunoglobulin kappa gene repertoire and somatic hypermutation patterns in follicular lymphoma
Bende et al. Immunoglobulin diversification in B cell malignancies: internal splicing of heavy chain variable region as a by-product of somatic hypermutation
US20050181370A1 (en) Cancer-associated nucleic acids and polypeptides
Li et al. Repertoire diversification in mice with an IgH-locus-targeted transgene for the rearranged VH domain of a physiologically selected anti-ssDNA antibody
US20050233353A1 (en) Methods and compositions for categorizing patients
EP4514952A1 (en) Terminal deoxynucleotidyl transferase antibodies and uses thereof
Neubauer et al. Gastric MALT lymphoma B cells express polyreactive, somatically mutated

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH

Free format text: FORMER NAME: NORTH SHORE-LONG ISLAND JEWISH RESEARCH INSTITUTE

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired